• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

Research & Development

J&J inks collab deal to develop MERS vaccine

September 27, 2018 By Fink Densford

Janssen

Healthcare giant Johnson & Johnson (NYSE:JNJ) today announced a new collaborative deal as it looks to develop a vaccine against Middle East Respiratory Syndrome Coronavirus. The collaborative deal is between J&J’s Janssen Vaccines & Prevention division, the Coalition for Epidemic Preparedness Innovations and The Jenner Institute at the University of Oxford, J&J said. Through the deal, Janssen […]

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: Janssen Pharmaceuticals, johnsonandjohnson

NIH kicks off study of combo antibody HIV therapy

September 21, 2018 By Sarah Faulkner

NIH IV bag

The National Institutes of Health reported this week that it launched a clinical trial evaluating a combination of antibodies in people with HIV. The early-stage study is designed to assess whether periodic infusions of two HIV-specific antibodies are safe in people living with HIV. Researchers also plan to gather preliminary data assessing how effectively the […]

Filed Under: Clinical Trials, Featured, Pharmaceuticals, Research & Development Tagged With: National Institutes of Health

EyeGate’s Phase 3 EGP-437 study fails to show non-inferiority

September 6, 2018 By Fink Densford

EyeGate Pharmaceuticals

Ophthalmalogical-focused developer EyeGate Pharma said this week that the Phase 3 study of its EGP-437 delivered through its EyeGate II drug delivery system did not show non-inferiority to the prednisolone acetate ophthalmic solution control group. The Phase 3 study was evaluating the safety and efficacy of the EGP-437 with the EyeGate II in patients with […]

Filed Under: Clinical Trials, Optical/Ophthalmic, Pharmaceuticals, Research & Development Tagged With: eyegatepharmaceuticals

Fujifilm backs therapeutic administration dev Suono Bio

September 5, 2018 By Fink Densford

Suono Bio

Suono Bio said today that Fujifilm (TSE:4901) made an undisclosed investment in the company to support its next-gen technology intended for the rapid, formulation-independent administration of therapeutics. The Cambridge, Mass.-based company, formed last year by researchers out of the Massachusetts Institute of Technology and Brigham & Women’s Hospital, is developing technology intended for the rapid local administration of […]

Filed Under: Business/Financial News, Research & Development Tagged With: Fujifilm Holdings, suonobio

Evidation, Tidepool pool resources on diabetes behavior study

August 24, 2018 By Nancy Crotti

Health measurement company Evidation Health and diabetes data firm Tidepool have launched a research program to study real-world data from people with type 1 diabetes. The T1D Sleep Pilot will develop insights from data generated by continuous glucose monitors and insulin pumps, in addition to sleep and activity trackers from smartphones and other connected sensors. The observational […]

Filed Under: Diabetes, Research & Development, Uncategorized Tagged With: evidationhealth, tidepool

Lessons learned: How Jeff Karp stays at the forefront of innovation

August 16, 2018 By Sarah Faulkner

DeviceTalks Boston promo

Serial entrepreneur Jeff Karp has a philosophy for his laboratory: find important problems and get solutions to people quickly. To learn about the exciting technologies emerging from Karp’s lab, join us at DeviceTalks Boston on Oct. 8-10. After Jeff finished his PhD in chemical and biomedical engineering at the University of Toronto, he knew he wanted […]

Filed Under: Featured, Pharmaceuticals, Research & Development Tagged With: DeviceTalks Boston, Frequency Therapeutics

Researchers use microparticles for targeted delivery of brain cancer therapy

August 7, 2018 By Sarah Faulkner

MIT - Glioma therapy

A team of researchers from Brigham & Women’s Hospital, Mass. Institute of Technology and Mass. General Hospital demonstrated that localizing the delivery of NAMPT inhibitors can extend survival in a mouse model of glioma, according to a paper published this week in the Proceedings of the National Academy of Sciences. The scientists created a test to […]

Filed Under: Drug-Device Combinations, Featured, Nanoparticles, Oncology, Pharmaceuticals, Research & Development Tagged With: Brigham & Women's Hospital, Massachusetts General Hospital, Massachusetts Institute of Technology

OncoSec inks research deal to analyze clinical trial participants

August 6, 2018 By Sarah Faulkner

OncoSec

OncoSec Medical (NSDQ:ONCS) said today that it inked a research deal with Dr. Roger Lo and his research team at the University of California Los Angeles to study participants from the biotech company’s Pisces/Keynote-695 Phase IIb clinical trial. Dr. Lo and his team are slated to perform genetic, transcriptomic and methylomic analyses of patients from OncoSec’s […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Oncology, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: OncoSec Medical

Catalent expands early-phase development skills with $139m Juniper buyout

July 3, 2018 By Sarah Faulkner

Catalent

Catalent (NYSE:CTLT) said today that it inked a $139 million deal to acquire Juniper Pharmaceuticals (NSDQ:JNP) and its early-stage product development services. The company noted that its Juniper acquisition, set at $11.50 per share, will complement Catalent’s formulation development offerings, bioavailability solutions and clinical-scale oral dose manufacturing capabilities. “Juniper’s proven solutions and capabilities will further support […]

Filed Under: Featured, Mergers & Acquisitions, Pharmaceuticals, Research & Development, Wall Street Beat Tagged With: Catalent, juniperpharmaceuticals

Generic drug shows promise as diabetes vaccine in small, years-long study

June 21, 2018 By Sarah Faulkner

diabetes

A cheap, generic tuberculosis vaccine lowered blood glucose levels in nine patients with Type I diabetes and the effects lasted for years, according to a study published this week in npj Vaccines. The study was conducted at Massachusetts General Hospital by Dr. Denise Faustman – a name that has long been saddled with controversy in the […]

Filed Under: Diabetes, Featured, Pharmaceuticals, Research & Development Tagged With: Massachusetts General Hospital

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Interim pages omitted …
  • Page 48
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS